Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance

Journal of Clinical Microbiology

Volumn 51, Issue 9, 2013, Pages 3127-3129

  Somoskovi, Akos ^a   Deggim, Vanessa ^a   Ciardo, Diana ^b   Bloemberg, Guido V ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Viollier AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; KATG PROTEIN; LEUCINE; PROLINE; RIFABUTIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; SERINE;

ACID FAST BACTERIUM; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CASE REPORT; DIAGNOSTIC ACCURACY; DIAGNOSTIC EQUIPMENT; DNA SEQUENCE; FALSE NEGATIVE RESULT; HUMAN; KATG GENE; LUNG TUBERCULOSIS; MALE; MTB RIF ASSAY; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RPOB GENE; SCREENING TEST; SEQUENCE ANALYSIS; SPUTUM ANALYSIS; SWITZERLAND;

AGED; BACTERIAL PROTEINS; BACTERIOLOGICAL TECHNIQUES; DRUG RESISTANCE, BACTERIAL; FALSE NEGATIVE REACTIONS; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84882745160     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01377-13     Document Type: Article

References (15)

1. Weyer K, Mirzayev F, Migliori G, Van Gemert W, D'Ambrosio L, Zignol M, Floyd K, Centis R, Cirillo D, Tortoli E, Gilpin C, Iragena J, Falzon D, Raviglione M. 2013. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert(R)MTB/RIF. Eur. Respir. J. 42:252-271.
2. Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA. 2012. An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis. 74:207-209.
3. Zbinden A, Keller PM, Bloemberg GV. 2011. Rapid molecular detection of tuberculosis. N. Engl. J. Med. 364:183; author reply 184-185.
4. Kent P, Kubica G. 1985. Public health mycobacteriology: a guide for the level III laboratory. Centers for Disease Control and Prevention, Atlanta, GA.
5. Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T. 1993. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob. Agents Chemother. 37:2054-2058.
6. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Bottger EC. 2009. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J. Clin. Microbiol. 47: 1773-1780.
7. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, Chakravorty S, Jones M, Alland D. 2010. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J. Clin. Microbiol. 48:2495-2501.
8. Lipsitch M, Levin BR. 1998. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int. J. Tuberc. Lung Dis. 2:187-199.
9. Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, Sanne I, Venter WF, Duse A, Stevens W. 2011. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 8:e1001061. doi: 10.1371/journal.pmed. 1001061.
10. Horne DJ, Pinto LM, Arentz M, Lin SY, Desmond E, Flores LL, Steingart KR, Minion J. 2013. Diagnostic accuracy and reproducibility of WHOendorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. J. Clin. Microbiol. 51:393-401.
11. Williamson DA, Roberts SA, Bower JE, Vaughan R, Newton S, Lowe O, Lewis CA, Freeman JT. 2012. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 16:216-220.
12. Van Deun A, Maug AK, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, de Jong BC. 2013. Rifampicin drug resistance tests for tuberculosis: challenging the gold standard. J. Clin. Microbiol. 51:2633-2640.
13. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, Rigouts L, Rusch-Gerdes S, Wright A. 2009. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J. Clin. Microbiol. 47:3501-3506.
14. Kurbatova EV, Cavanaugh JS, Shah NS, Wright A, Kim H, Metchock B, Van Deun A, Barrera L, Boulahbal F, Richter E, Martin-Casabona N, Arias F, Zemanova I, Drobniewski F, Santos Silva A, Coulter C, Lumb R, Cegielski JP. 2012. Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. Int. J. Tuberc. Lung Dis. 16:355-357.
15. Mukinda FK, Theron D, van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, Musekiwa A, Coetzee GJ, Victor TC, Marais BJ, Nachega JB, Warren RM, Schaaf HS. 2012. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int. J. Tuberc. Lung Dis. 16: 196-202.